Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study

Author:

De Lena M.,Lorusso V.,Latorre A.,Fanizza G.,Gargano G.,Caporusso L.,Guida M.,Catino A.,Crucitta E.,Sambiasi D.,Mazzei A.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference20 articles.

1. Ozols RF, Schwartz PE, Eifel PJ. Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma. In De Vita VT, Hellman S, Rosenberg SA, eds. Cancer Principles and Practice of Oncology. Philadelphia, JB Lippincott, 1997, 5th edn. 1502–1539.

2. New therapy for ovarian cancer;Neijt;N. Engl. J. Med.,1996

3. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;Mc Guire;N Engl J Med.,1996

4. Stuart G, Bertelsen K, Mangioni C, et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc Am Soc Clin Oncol 1998, 17, 1373 (abstr).

5. Ozols RF, Bundy BN, Fowler J, et al. Randomized phase III trial study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 1999, 18, 1373 (abstr).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3